ClinicalTrials.gg
Not yet recruitingNCT07454668Updated Oct 1, 2026

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

A Phase 1 interventional study of Trastuzumab Deruxtecan and Stereotactic Radiosurgery in Breast Cancer, HER2-positive Breast Cancer and Brain Metastases, sponsored by Baptist Health South Florida. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Baptist Health South Florida · Phase 1, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 1, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms — 32 open to participants now, 46 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Planned enrollment
53rd of 59
20 · median 138
Started
2027
with 2 others
Phase 1
6 of 59
1 open now
Primary completion
2029-02
later than 34 of 45 live
Registered
51st of 59
by date
Lead sponsor
1 of 59
Baptist Health South Florida

Among the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 53rd largest by planned enrollment, is one of 3 that started in 2027, is one of 6 in phase 1, reaches primary completion later than 34 of the 45 other live ones, and was the 51st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.

03

Conditions studied

  • Breast Cancer
  • HER2-positive Breast Cancer
  • Brain Metastases
  • Cancer
  • Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed -positive breast cancer with newly diagnosed .
  2. Performance Status (PS) of 0, 1, 2.
  3. Participants with 1-10 brain metastases will be candidates for T-DXd with SRS at the discretion of the treating radiation oncologist. Intra-cranial must measure 3 cm or less in the greatest dimension.
  4. Age ≥ 18 years
  5. Signed written by patient or legally authorized representative. A signed informed consent must be obtained prior to any study-specific procedures.
  6. of at least 12 weeks.
  7. Any number of prior systemic therapies will be allowed, except T-DXd.
  8. ≥ 9 g/dL, White blood count ≥ 3.0 × 109/L, ≥ 1.5 × 109/L and count ≥ 100 × 109/L.
  9. Serum ≤ 1.5 × (ULN).
  10. and/or ALT ≤ 2 × ULN (≤ 5 × ULN when clearly attributable to the presence of liver metastases).
  11. Serum creatinine ≤ 1.5 × ULN or calculated > 60 mL/min.
  12. Ability to comply with study procedures and monitoring.
  13. For individuals of , a negative pregnancy test should be obtained within 7 days prior to the start of therapy.
  14. Participants must have (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before enrollment (to be assessed as clinically indicated).
  15. Male or female participants of need to employ two highly effective and acceptable forms of throughout their participation in the study and for 7 months after last dose of T-DXd.

Highly effective and acceptable forms of contraception are:

  • Male condom plus spermicide
  • Cap plus spermicide
  • Diaphragm plus spermicide
  • Copper T
  • Progesterone T
  • Levonorgestrel-releasing intrauterine system (e.g., Mirena®)
  • Implants
  • Hormone shot or injection
  • Combined pill
  • Mini-pill
  • Patch

individuals on the study (that will not need contraception) is defined as:

  • Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments.
  • LH and FSH levels in the postmenopausal range for individuals \< 50 years.
  • Radiation-induced oophorectomy with last menses > 1 year ago.
  • Chemotherapy-induced menopause with > 1 year interval since last menses.
  • Surgical sterilization (bilateral oophorectomy or hysterectomy).

Men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  1. Participants with documented by MRI or CSF evaluation.
  2. Evidence of intra-tumoral or peri-tumoral hemorrhage deemed by the treating physician.
  3. within 5 mm of the optic chiasm or optic nerve.
  4. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom, e.g., Crohn's disease, malabsorption, or grade > 2 diarrhea of any etiology at baseline.
  5. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, (NYHA) functional classification of 3 or 4.
  6. Unable to undergo brain MRI.
  7. Screen for (HIV) infection or chronic or C. HIV/HBV/ testing per institutional practice.
  8. All toxicities from prior therapies must have resolved to CTCAE v5.0 grade 1 or better by the time of study enrollment.
  9. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active, or uncontrolled infection, uncontrolled diabetes, second active ) that could cause unacceptable safety risks or compromise compliance with the protocol.
  10. Currently receiving other cancer therapy (with the exception of continuing therapy with GnRH analogues) within 4 weeks prior to start of study treatment.
  11. Mean corrected heart rate (QTc) ≥ 470 ms calculated from 3 using Fredericia's Correction, calculated as: 8.22 ∛(RR interval)
  12. \<50%.
  13. Ineligible for treatment with T-DXd.
  14. Ineligible for treatment with SRS.
  15. Active or prior documented ILD/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  16. History of to T-DXd.
  17. History and/or confirmed corneal ulceration.
  18. Pregnant or breast feeding. The patients should not breast feed for 7 months after stopping the drug.
  19. Use of anthracyclines will be prohibited while on the protocol.
  20. Prior cranial radiation is not allowed.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    T-DXd + SRS

    All participants will receive SRS and the drug T-DXd. The goal is to evaluate safety and determine an appropriate dose.

    Drug: Trastuzumab Deruxtecan · Radiation: Stereotactic Radiosurgery

Interventions

  • T-DXd will be given as an IV infusion every 21 days. This Phase 1 study will use predefined dose levels (5.4 mg/kg, 4.4 mg/kg, and 3.2 mg/kg) to evaluate safety and tolerability. Participants may continue treatment until disease progression, unacceptable side effects, or withdrawal.

    Also known as: T-DXd

  • RadiationStereotactic Radiosurgery

    Participants will receive SRS to intact brain metastases. Typical dosing is 20-24 Gy in a single fraction for lesions \<20 mm, or 27 Gy in 3 fractions for lesions ≥20 mm. Exact dosing will be based on the treating radiation oncologist's clinical judgment.

    Also known as: SRS

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    DLTs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 starting from the first dose of T-DXd through 3 weeks after SRS. DLT is defined as the appearance of side effects during treatment that are severe enough to prevent continuation of treatment at a participant's assigned dose. Any of the following events will be considered a DLT if treatment-related: * ≥ Grade 4 non-hematologic toxicity except nausea and vomiting (if manageable with supportive care measures), alopecia, drug-related fever, and toxicities secondary to neutropenia and sepsis * ≥ Grade 3 neurologic toxicity (sensory or autonomic) * Grade 4 platelet count (\<25,000/mm³) 50 days beyond the start of the most recent chemotherapy (not related to recurrent leukemia) * Grade 4 neutropenia 50 days beyond the start of the most recent chemotherapy (not related to recurrent leukemia) * Grade 3 non-hematologic toxicity (excluding alopecia or toxicities secondary to neutropenia

    Time frame: 3 weeks

  2. Determination of the maximum tolerated dose (MTD) of T-DXd in combination with SRS

    The MTD will be determined using a standard 3+3 dose de-escalation design across predefined dose levels of T-DXd (5.4 mg/kg, 4.4 mg/kg, and 3.2 mg/kg IV every 21 days), based on the number of participants who experience a DLT at each dose level.

    Time frame: 3 weeks

Secondary outcomes

  1. Intracranial Progression-free survival (PFS) at 6 months (PFS-6)

    Intracranial PFS-6 will be defined as the time from first dose of study drug until intracranial disease progression (i.e., progression within the skull) or death from any cause using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) at 6 months post-treatment. Progression is defined as at least 20% increase in the sum of the longest diameters of the target lesions, appearance of any new lesions, or unequivocable progression of any non-target lesions. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.

    Time frame: 6 months

  2. Extracranial PFS-6

    Extracranial PFS-6 will be defined as the time from first dose of study drug until extracranial disease progression (i.e., progression outside of the skull) or death from any cause using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) at 6 months post-treatment. Progression is defined as at least 20% increase in the sum of the longest diameters (LD) of the target lesions compared to the smallest recorded LD since treatment started, appearance of any new lesions, or unequivocable progression of any non-target lesions. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.

    Time frame: 6 months

  3. Overall survival (OS)

    Median OS will be defined as the time from the beginning of study drug treatment until death due to any cause at the end of the study (\~2 years). For participants who have not died at the time of the analysis, censoring will be performed using the date the participant was last known to be alive.

    Time frame: 2 years

  4. Objective response rate (ORR)

    ORR will be defined as the proportion of participants achieving a complete response (CR) or partial response (PR) using RECIST v1.1 as their best overall response by the end of the study (\~2 years). Participants with CR or PR will be counted as successes and all other participants (including those with missing response information) will be counted as failures. CR is defined as disappearance of all target and non-target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. All lymph nodes must be non-pathological in size (\<10 mm short axis). PR is defined as at least 30% decrease in the sum of the LD of target lesions compared to baseline. There can be no appearance of new lesions.

    Time frame: 2 years

  5. Intracranial PFS-6 comparison to historical data

    Intracranial PFS-6 as defined in Outcome 3 will be compared to historical data.

    Time frame: 6 months

  6. Extracranial PFS-6 comparison to historical data

    Extracranial PFS-6 as defined in Outcome 4 will be compared to historical data.

    Time frame: 6 months

  7. OS comparison to historical data

    Median OS as defined in Outcome 5 will be compared to historical data.

    Time frame: 2 years

  8. ORR comparison to historical data

    ORR as defined in Outcome 6 will be compared to historical data.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Feb 2029, 25 months later.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 25 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Jun 2026 → Jan 2027, primary completion Jul 2028 → Feb 2029 and completion Jul 2029 → Feb 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Mar 6, 2026
StartEst.
Jan 2027was Jun 2026
Primary completionEst.
Feb 2029was Jul 2028
CompletionEst.
Feb 2030was Jul 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Baptist Health Herbert Wertheim Cancer Institute · Miami, United States
Show 1 removed
  • Miami Cancer Institute at Baptist Health, Inc. · Miami, United States
Oct 1, 2026
Start date
Jun 2026→Jan 2027
Oct 1, 2026
Primary completion
Jul 2028→Feb 2029
Oct 1, 2026
Study completion
Jul 2029→Feb 2030
Oct 1, 2026
Contact
Study contact changed: C•••@baptisthealth.net · •••2000→M•••@baptisthealth.net · •••2000. See the current contact
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Baptist Health Herbert Wertheim Cancer Institute · Miami, United States
    Show 1 removed
    • Miami Cancer Institute at Baptist Health, Inc. · Miami, United States
    Start date Jun 2026→Jan 2027
    Primary completion Jul 2028→Feb 2029
    Study completion Jul 2029→Feb 2030
    Contact Study contact changed: C•••@baptisthealth.net · •••2000→M•••@baptisthealth.net · •••2000. See the current contact
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07454668
Lead sponsor
Baptist Health South Florida
Collaborators
National Brain Tumor Society
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Jan 2027 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Feb 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Manmeet Ahluwalia, M.D.
Contact
ManmeetA@baptisthealth.net
786-596-2000
Multisite Research Program
Contact
MCIMultisiteResearch@baptisthealth.net
786-596-2000
Manmeet Ahluwalia
principal investigator · Baptist Health Herbert Wertheim Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion